Mucopolysaccharidosis Type I

Mucopolysaccharidosis Type I

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Mucopolysaccharidosis Type I is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • Hurler Disease
  • Gargoylism
  • MPS Disorder I
  • MPS I

Disorder Subdivisions

  • Scheie Syndrome (MPS IS)
  • Hurler-Scheie Syndrome (MPS IH/S)
  • Hurler Syndrome (MPS IH)

General Discussion

Mucopolysaccharidoses (MPS disorders) are a group of rare genetic disorders caused by the deficiency of one of ten specific lysosomal enzymes, resulting in an inability to metabolize complex carbohydrates (mucopolysaccharides) into simpler molecules. The accumulation of these large, undegraded mucopolysaccharides in the cells of the body causes a number of physical symptoms and abnormalities.



Mucopolysaccharidosis type I (MPS I) is a form of MPS caused by a deficiency of the enzyme alpha-L-iduronidase. The most severe form of MPS I is often called Hurler syndrome (or MPS IH). It is named for the physician, Gertrud Hurler, who first described the disorder in 1919. A milder form of MPS I is called Scheie syndrome (or MPS IS), and the name Hurler-Scheie (MPS IH/S) is sometimes applied to an intermediate form that does not fit clearly in either the milder or more severe category.

Symptoms

Infants with MPS I usually appear normal at birth, but may have inguinal and umbilical hernias. The diagnosis of MPS I is commonly made between 6 and 24 months of age when the patient may exhibit coarse facial features, clouding of the cornea, enlarged liver and spleen, a large tongue, skeletal abnormalities, poor growth, joint stiffness, and a prominent forehead.



MPS IH or Hurler syndrome, the most severe form of MPS I, is characterized by high concentrations of mucopolysaccharides, dermatan and heparan sulfates in the urine. Symptoms first become evident at 6 months to 2 years of age with developmental delay, recurrent urine and upper respiratory infections, noisy breathing and a persistent nasal discharge. Hydrocephalus is commonly present after the age of 2-3 years. (For more information on this disorder, choose "hydrocephalus" as your search term in the Rare Disease Database.) Other physical manifestations of this disorder may include clouding of the cornea of the eye, unusually large tongue, misaligned teeth, the development of a curved back and severe joint stiffness with clawlike hands. Mental development of Hurler syndrome usually reaches a peak at about 2 years of age with progressive mental retardation thereafter.



In the milder form of MPS I, known as Scheie syndrome, patients typically have normal intelligence, stature and life expectancy, but suffer from physical symptoms such as stiff joints, clouding of the cornea, and flow of blood from the aorta back into the left ventricle of the heart (aortic regurgitation). The onset of symptoms in patients with Scheie syndrome usually occurs after the age of 5 years. However, diagnosis is commonly delayed to between 10 to 20 years of age.



Hurler-Scheie syndrome, the intermediate form, is characterized by normal intelligence but progressive physical involvement which is milder than the physical signs and symptoms associated with Hurler syndrome. Corneal clouding, joint stiffness, deafness and valvular heart disease can develop by the early to mid-teens, causing significant impairment.

Causes

Signs and symptoms of MPS I occur as a result of a deficiency of the enzyme, alpha-L-iduronidase deficiency, needed to break down or metabolize complex carbohydrates (mucopolysaccharides).



The disorder is transmitted genetically, with each parent contributing one recessive gene carrying exactly the same type of genetic inheritance. Human traits including the classic genetic diseases, are the product of the interaction of two genes for that condition, one received from the father and one from the mother.



In recessive disorders, the condition does not appear unless a person inherits the same defective gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk of transmitting the disease to the children of a couple, both of whom are carriers for a recessive disorder, is 25 percent. Fifty percent of their children risk being carriers of the disease, but generally will not exhibit symptoms of the disorder. Twenty-five percent of their children may receive both normal genes, one from each parent, and will be genetically normal (for that particular trait). The risk is the same for each pregnancy.

Affected Populations

MPS I tends to affect males and females equally with an incidence of about 1 in 100,000 live births.

Standard Therapies

Diagnosis

Prenatal diagnosis of MPS I is now possible through amniocentesis and sampling of a tissue layer in the embryo (chorionic villus sampling).



Treatment

Laronidase (Aldurazyme), an enzyme replacement therapy, has been approved by the U.S. Food and Drug Administration (April 2003) for treating patients with the Hurler and Hurler-Scheie forms of MPS I and for patients with the Scheie form who exhibit moderate to severe symptoms. Aldurazyme is manufactured by BioMarin Pharmaceutical Inc. and the Genzyme Corporation. It is the first treatment approved specifically for Hurler syndrome. For information about Aldurazyme, contact:



BioMarin Pharmaceutical Inc.

105 Digital Drive

Novato, CA 94949

Telephone: (415) 506-6700

Fax: (415) 382-7889

Patient Information: (415) 506-6100



Genzyme Corporation

500 Kendall Street

Cambridge, MA 02142

Telephone: (617) 252-7500

Fax: (617) 252-7600



Other treatment is symptomatic and supportive. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, specialists who assess and treat disorders of the nervous system (neurologists), specialists who diagnose and treat skeletal abnormalities (orthopedists), specialists who diagnose and treat heart abnormalities (cardiologists), physical therapists, and/or additional health care professionals may need to systematically and comprehensively plan an affected child's treatment. Medical and genetic counseling services will be useful to affected individuals and family.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government Web site.



For information about clinical trials conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

E-mail: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com



Scientists are studying the replacement of defective enzymes via enzyme replacement therapies and/or bone marrow transplants. Scientific study of gene replacement in animal models raises the hope that gene replacement therapy may someday be made available to people with genetic disorders such as MPS.



Fairview University Medical Center in Minneapolis is sponsoring a phase II study of bone marrow or umbilical cord blood transplantation in patients with MPS I and other lysosomal storage (and related) disorders. This study is sponsored by Fairview University Medical Center. For information, contact the study chair, Charles Peters, at (612) 624-5407.



Physicians at the Cedars-Sinai Medical Center and the Children's Hospital Los Angeles are investigating the use of in utero bone marrow transplantation (BMT) to treat specific genetic conditions. Cells isolated from the father's bone marrow are transplanted during the first trimester of pregnancy (before 14 weeks of gestation) in fetuses with a confirmed diagnosis of Wiskott-Aldrich syndrome, chronic granulomatous disease, alpha thalassemia, MPS I, metachromatic leukodystrophy and Krabbe disease. The diagnosis must be confirmed before 11 weeks of gestation. Other MPS storage disorders are not eligible for this study currently. For more information, contact:



Dr. Rena Falk or Dr. William Wilcox

Division of Genetics

Ceders-Sinai Medical Center

444 S. San Vicente Blvd. Suite 1001

Los Angeles, CA 90048

Tel: (310) 855-6451

Fax: (310) 659-0491

E-mail: rfalk@mailgate.csmc.edu

or wwilcox@mailgate.csmc.edu



or



Dr. Robert Parkman

Division of Transplant Immunology

Children's Hospital Los Angeles

4650 Sunset Blvd.

Los Angeles, CA 90027

(213) 669-2546

e-mail: rparkman%smtpgate@chlais.usc.edu



Following the FDA approval of laronidase (Aldurazyme) for treating patients with Hurler syndrome, the companies sponsoring this enzyme replacement therapy, BioMarin Pharmaceutical Inc. and the Genzyme Corporation, have agreed with the FDA on a number of post-marketing commitments, including obtaining long-term information related to the natural history of MPS and the safety and efficacy of Aldurazyme. For information on how to contact these companies, see the Standard Therapies section of this report.



Contact for additional information about mucopolysaccharidosis type I:



John Barranger, PhD, MD

Director, Lysosomal Storage Disease, Clinical Care Network

412-735-5462

lsdccn@gmail.com

References

TEXTBOOKS

Fauci AS, et al., eds. Harrison's Principles of Internal Medicine, 14th Ed. New York, NY: McGraw-Hill, Inc; 1998:2169-76.



Behrman RE, ed. Nelson Textbook of Pediatrics, 15th ed. Philadelphia, PA: W.B. Saunders Company; 1996:398-403.



Scriver CR, et al., eds. The Metabolic and Molecular Basis of Inherited Disease. 7th Ed. New York, NY; McGraw-Hill Companies, Inc; 1995:2465-85.



Beighton P, ed. Mckusick's Heritable Disorders of Connective Tissue. 5th ed. St. Louis, MO: Mosby-Year Book, Inc; 1993:1118-9.



JOURNAL ARTICLES

Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J. Inherit Metab Dis. 2004;27:385-410.



Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144:581-88.



Staba SL, et al. Cord-blood transplants from unrelated donors in patients with Hurler's Ssyndrome. N Engl J Med. 2004;350:1960-69.



Muenzer J and Fisher A. Advances in the Treatment of Mucopolysaccharidosis Type I. New Engl J Med. 2004;350:1932-34.



Malm G, et al., Mucopolysaccharidoses. New therapeutic possibilities increase the need of early diagnosis. Lakartidningen. 2002;99:1804-9.



Kakkis ED, Enzyme replacement therapy for the mucopolysaccharides storage disorders. Expert Opin Investig Drugs. 2002;11:675-85.



Wraith JE, Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis. 2001;24:245-50.



Kakkis ED, et al., Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344:182-8.



Eto Y, Ohashi T, Gene therapy/cell therapy for lysosomal storage disease. J Inherit Metab Dis. 2000;293-8.



Triggs-Raine B, et al., Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci USA. 1999;95:6296-300.



Natowicz MR, et al., Clinical biochemical manifestations of hyaluronidase deficiency. N Engl J Med. 1996;335:1029-33.



Herrick IA, et al., The mucopolysaccharidoses and anaesthesia: a report of clinical experience. Can J Anaesth. 1988;35:67-73.



Sjogren P, et al., Mucopolysaccharidoses and anaesthetic risks. Acta Anaesthesiol Scand. 1987;31:214-8.



Caruso RC, et al., Electroretinographic findings in the mucopolysaccharidoses. Ophthalmology. 1986;93::1612-6.



FROM THE INTERNET

McKusick VA., ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No: 252800; Last Update:1/2/02; Entry No:309900; Last Update:4/8/02; Entry No:252900; Last Update:2/25/02; Entry No:252920; Last Update:10/2/02; Entry No:252930; Last Update:3/28/01; Entry No:252940; Last Update:9/17/01; Entry No:253000; Last Update:1/2/03; Entry No:253010; Last Update:5/1/02; Entry No:253200; Last Update:6/10/02; Entry No:253220; Last Update:12/10/02; Entry No:253230; Last Update:2/8/96; Entry No:601492; Last Update:6/26/02.

Resources

CLIMB (Children Living with Inherited Metabolic Diseases)

Climb Building

176 Nantwich Road

Crewe, CW2 6BG

United Kingdom

Tel: 4408452412173

Fax: 4408452412174

Email: enquiries@climb.org.uk

Internet: http://www.CLIMB.org.uk



The Arc

1825 K Street NW, Suite 1200

Washington, DC 20006

Tel: (202)534-3700

Fax: (202)534-3731

Tel: (800)433-5255

TDD: (817)277-0553

Email: info@thearc.org

Internet: http://www.thearc.org



National MPS Society, Inc.

PO Box 14686

Durham, NC 27709

Tel: (919)806-0101

Fax: (919)806-2055

Tel: (877)677-1001

Email: info@mpssociety.org

Internet: http://www.mpssociety.org



Society for Mucopolysaccharide Diseases

MPS House

Repton Place

White Lion Road

Amersham

Buckinghamshire, HP7 9LP

United Kingdom

Tel: 08453899901

Fax: 08453899902

Email: mps@mpssociety.co.uk

Internet: http://www.mpssociety.co.uk



Canadian Society for Mucopolysaccharide and Related Diseases, Inc.

PO Box 30034

RPO Parkgate

North Vancouver

British Columbia, V7H 2Y8

Canada

Tel: 6049245130

Fax: 6049245131

Tel: 8006671846

Email: info@mpssociety.ca

Internet: http://www.mpssociety.ca



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766

Email: getinfo@madisonsfoundation.org

Internet: http://www.madisonsfoundation.org



Let Them Hear Foundation

1900 University Avenue, Suite 101

East Palo Alto, CA 94303

Tel: (650)462-3174

Fax: (650)462-3144

Email: info@letthemhear.org

Internet: http://www.letthemhear.org



Hide & Seek Foundation for Lysosomal Disease Research

6475 East Pacific Coast Highway Suite 466

Long Beach, CA 90803

Tel: (877)621-1122

Fax: (866)215-8850

Email: info@hideandseek.org

Internet: http://www.hideandseek.org



Medical Home Portal

Dept. of Pediatrics

University of Utah

P.O. Box 581289

Salt Lake City, UT 84158

Tel: (801)587-9978

Fax: (801)581-3899

Email: mindy.tueller@utah.edu

Internet: http://www.medicalhomeportal.org



Proyecto Pide un Deseo México, i.a.p.

Altadena #59-501 col. Napoles

delegacion Benito Juarez

03810 Mexico D.F.

Tel: 55 5543-2447

Fax: 55-5543-5450

Email: prayecto.pdeundese.mexico@gmail.com

Internet: http://www.pideundeseo.org



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.